Dispute flares within FDA over safety of popular blood pressure drugs

The top-selling class of blood-pressure drugs is under attack from an unusual source: a senior regulator at the Food and Drug Administration. Bucking his bosses, Thomas A. Marciniak is seeking stronger warnings about the drugs known as angiotensin receptor blockers, or ARBs, according to… http://healthmedicinet.com/i/dispute-flares-within-fda-over-safety-of-popular-blood-pressure-drugs-2/